Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. CHARLOTTE, N.C.–(BUSINESS

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

Cannabis Law Report

SEPTEMBER 14, 2021

A lack of consumer trust, transparency and scientific rigor has hampered the CBD and cannabinoid industry from reaching its growth potential for far too long”.

Extraction 52

Extraction Research and Development Clinical Trials CBD 52

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

The Joint Blog

JANUARY 23, 2020

.” For this study, “The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted.” One isolated study indicates some potential efficacy for an oral cannabinoid /terpene combination in ADHD.

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

Greencamp

AUGUST 16, 2018

Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. The first study I will reference is from 2006, conducted on mice.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Healer

MARCH 26, 2021

THC is the main psychoactive compound in marijuana, while CBD is a non-intoxicating cannabinoid found in the cannabis plant. Seventeen of 19 pre-clinical studies provided “robust” evidence of the opioid-sparing effects of cannabinoids, but one of the nine clinical studies provided “very low-quality” evidence of such, according to the review.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

The Joint Blog

APRIL 17, 2020

Over the past few decades, there has been an increased interest in leveraging cannabis and cannabinoids for medicinal purpose. Crohn’s ), chronic pain , appetite loss , issues with sleep , immune system disorders , thermoregulation problems, cancer and more. However, in some cases, the risks may outweigh even the proven benefits.

Events 48

Events THC Chronic Pain Sleep 48

Veriheal

JANUARY 5, 2023

A separate report published by Data Bridge Market research spotlighted the sheer size of the CBD market. The cannabinoid is being utilized for a broad spectrum of medical problems, such as chronic pain, stress, anxiety, sleep/insomnia, skin care, migraine, seizures, neurological conditions, and inflammation. Senate approval.

Clinical Trials 82

Clinical Trials Safety Consumption CBD 82

Project CBD

FEBRUARY 27, 2023

Researchers have been investigating the use of cannabis to treat fibromyalgia’s constellation of symptoms for decades, with early clinical trials in the 2000s 1-4 suggesting a possible benefit of both pure THC and flower in managing the disease. It’s not a new idea.

THC 144

THC CBD Sleep Clinical Trials 144

Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

The Cannigma

JANUARY 13, 2023

The ECS touches on nearly every biological function you have, including sleep, pain, appetite, body temperature, immune function, memory, and hormone regulation. Since pain and nausea are two of the most common symptoms of migraines, this cannabinoid is of great scientific interest in helping people who suffer from migraines.

Terpenes 132

Terpenes Strains THC Treatment 132

Cannabis Law Report

JANUARY 9, 2019

Phoenix, headquartered in Denver, distributes medicinal cannabis products around the globe to treat seven major categories of medical conditions including pain, cancer, autoimmune, metabolic, neurological, psychological and sleep disorders. Tindall also hope to commence the clinical trials with Vanuatu for diabetes treatment.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

The Joint Blog

FEBRUARY 18, 2020

According to NORML, they reported that the use of medical cannabis, and in particular products dominant in the cannabinoid CBN (cannabinol), was associated with medication-sparing effects. The study is titled Cannabinoid and terpenoid doses are associated with adult ADHD status of medical cannabis patients.

Clinical Trials 45

Clinical Trials Terpenes Data Cannabinoids 45

Green Relief

MAY 13, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

government-held patent pertaining to “cannabinoids as antioxidants and neuroprotectants,” CBD and THC can limit “neurological damage following ischemic insults, such as stroke or trauma.”. As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Data collection. This offers a more denotative approach to complement the data.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 12, 2021

Diamandis joins Radicle Science as the healthtech company accelerates growth with industry veteran Sheldon Borkin PhD as CTO, the launch of a first of its kind real-world sleep study, and updates on significant milestones this year. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

DECEMBER 7, 2021

The four-week Institutional Review Board (IRB) approved randomized controlled trial (RCT) of nearly 3,000 participants assigned to different botanical products containing CBD revealed significant improvement across all five health outcomes studied: well-being, quality of life, longer-term pain, feelings of anxiety, and sleep quality.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. Drug Science. Matthew Johnson. Johns Hopkins University. in/ingmargorman/ [link]. James Keim.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51